Dapagliflozin or saxagliptin in pediatric type 2 diabetes: a plain language summary

This Plain Language Summary of Publication article (PLSP) from Current Medical Research & Opinion, highlights the T2NOW clinical trial, which tested the blood sugar-reducing drugs dapagliflozin and saxagliptin in young people aged 10 to 17 with type 2 diabetes. The trial compared each drug with a placebo to assess blood sugar control and side effects. Type 2 diabetes is becoming more common in younger individuals, often due to childhood obesity, and early onset can lead to serious health issues. While diet and exercise are crucial, treatment options for children and adolescents remain limited.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes’ and was published in NEJM Evidence.

Visit NEJM using the link to read the original article.